Neurobiology of depression: New data;Approche neurobiologique de la dépression: Nouvelles données

Therapie

Volumn 60, Issue 5, 2005, Pages 431-440

  Lanfumey, Laurence ^a   Hamon, Michel ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Depression; Neurogenesis; Neurohormones; Neuropeptides; Serotonin

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; AGOMELATINE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; GLUCOCORTICOID; IMIPRAMINE; IPRONIAZID; ISONIAZID; MILNACIPRAN; MONOAMINE; MONOAMINE OXIDASE INHIBITOR; NEUROKININ 1 RECEPTOR ANTAGONIST; NEUROPEPTIDE; PINDOLOL; SEROTONIN; SEROTONIN 1A ANTAGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN 1B ANTAGONIST; SEROTONIN 1B RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN 3 RECEPTOR; SEROTONIN 7 RECEPTOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

CARDIOTOXICITY; CELL FUNCTION; CHRONIC DRUG ADMINISTRATION; CORTICOSTEROID THERAPY; DRUG EFFECT; DRUG SELECTIVITY; DRUG TARGETING; EXPERIMENTAL MOUSE; HIPPOCAMPUS; HUMAN; HYPERTENSION; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MAJOR DEPRESSION; MENTAL STRESS; MOLECULAR BIOLOGY; MONOAMINERGIC SYSTEM; MOOD DISORDER; NERVOUS SYSTEM DEVELOPMENT; NEUROBIOLOGY; NONHUMAN; PATHOPHYSIOLOGY; POSTNATAL DEVELOPMENT; PRIORITY JOURNAL; PSYCHIATRIC TREATMENT; RECEPTOR BLOCKING; REPRODUCIBILITY; REVIEW; RODENT; SEROTONINERGIC SYSTEM; UPREGULATION; DEPRESSION; NERVE CELL; PHYSIOLOGY;

DEPRESSION; DEPRESSIVE DISORDER; HUMANS; NEUROBIOLOGY; NEURONS; NEUROPEPTIDES; SEROTONIN;

EID: 33645240107     PISSN: 00405957     EISSN: 00405957     Source Type: Journal    
DOI: 10.2515/therapie:2005064     Document Type: Article

References (80)

1. Loomer HP, Saunders JC, Kline NS. A clinical and pharmacodynamic evaluation of iproniazid as a psychic energizer. Psychiatr Res Rep Am Psychiatr Assoc 1957; 135: 129-41
2. Kuhn R. The treatment of depressive states with G 22355 (imipramine hydrochloride). Am J Psychiatry 1958; 115: 459-64
3. Maes M, Meltzer HY. The serotoninergic hypothesis of depression. In: Bloom FE, Kupfer DJ, editors: Psychopharmacology: the fourth generation of progress. New York: Raven Press, 1995: 921-32
4. Preskorn SH, Irwin HA. Toxicity of tricyclic antidepressants: kinetics, mechanism, intervention: a review. J Clin Psychiatry 1982; 43: 151-6
5. Lecrubier Y. Risk-benefit assessment of newer versus older monoamine oxidase (MAO) inhibitors. Drug Saf 1994; 10: 292-300
6. Hamon M. New perspectives in the serotoninergic treatment for depression. Therapie 1995; 50: 505-9
7. Asberg M. Neurotransmitters and suicidal behavior: the evidence from cerebrospinal fluid studies. Ann N Y Acad Sci 1997; 836: 158-81
8. Delgado PL, Charney DS, Price LH, et al. Serotonin function and the mechanism of antidepressant action: reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry 1990; 47: 411-8
9. Fuller RW, Wong DT. Inhibition of serotonin reuptake. Fed Proc 1977; 36: 2154-8
10. 1B receptors and 5-HT transporter in rats treated chronically with fluoxetine. Neuropharmacology 2000; 39: 110-22
11. Blier P. The pharmacology of putative early-onset antidepressant strategies. Eur Neuropsychopharmacol 2003; 13: 57-66
12. 1A receptors. In: Baumgarten HG, Göthert M, editors. Serotoninergic neurons and 5-HT receptors in the CNS, handbook of experimental pharmacology. Berlin: Springer-Verlag, 1997: 239-68
13. Blier P, De Montigny C. Electrophysiological investigations on the effect of repeated zimelidine administration on serotoninergic neurotransmission in the rat. J Neurosci 1983; 3: 1270-8
14. 1A receptor-mediated regulation of dorsal raphe and hippocampal cell activity. J Neurosci 2001; 21: 2178-85
15. Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 2002; 71: 533-54
16. Raymond JR, Mukhin YV, Gelasco A, et al. Multiplicity of mechanisms of serotonin receptor signal transduction. Pharmacol Ther 2001; 92: 179-212
17. 1B serotonin receptors in adult rat brain. J Comp Neurol 2000; 417: 181-94
18. 2 receptors. Curr Drug Targets CNS Neurol Disord 2004; 3: 11-26
19. 7 receptors. Curr Drug Targets CNS Neurol Disord 2004; 3: 81-90
20. Arango V, Underwood MD, Gubbi AV, et al. Localized alterations in pre- and postsynaptic serotonin binding sites in the ventrolateral prefrontal cortex of suicide victims. Brain Res 1995; 688: 121-33
21. 2 receptors in suicide victims. Biol Psychiatry 1994; 35: 457-63
22. Arango V, Underwood MD, Boldrini M, et al. Serotonin 1A receptors, serotonin transporter binding and serotonin transporter mRNA expression in the brainstem of depressed suicide victims. Neuropsychopharmacology 2001; 25: 892-903
23. Stockmeier CA, Shapiro LA, Dilley GE, et al. Increase in serotonin-1A autoreceptors in the midbrain of suicide victims with major depression- postmortem evidence for decreased serotonin activity. J Neurosci 1998; 18: 7394-401
24. Mayorga AJ, Dalvi A, Page ME, et al. Antidepressant-like behavioral effects in 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B) receptor mutant mice. J Pharmacol Exp Ther 2001; 298: 1101-7
25. Artigas F, Celada P, Laruelle M, et al. How does pindolol improve antidepressant action? Trends Pharmacol Sci 2001; 22: 224-8
26. Cremers TI, Wiersma LJ, Bosker FJ, et al. Is the beneficial antidepressant effect of coadministration of pindolol really due to somatodendritic autoreceptor antagonism? Biol Psychiatry 2001; 50: 13-21
27. Fabre V, Hamon M. Mechanisms of action of antidepressants: new data from escitalopram. Encephale 2003; 29: 259-65
28. von Euler US, Gaddum JH. An unidentified depressor substance in certain tissue extracts. J Physiol (Lond) 1931; 72: 74-87
29. Chang MM, Leeman SE, Niall HD. Amino-acid sequence of substance P. Nat New Biol 1971; 232: 86-7
30. Hokfelt T, Pernow B, Wahren J. Substance P: a pioneer amongst neuropeptides. J Intern Med 2001; 249: 27-40
31. Dietl MM, Torrens Y. Substance P et tachykinines. In: Epelbaum J, editor. Neuropeptides et neuromédiateurs. Paris: Sandoz / Les Editions INSERM, 1995: 281-93
32. Severini C, Improta G, Falconieri-Erspamer G, et al. The tachykinin peptide family. Pharmacol Rev 2002; 54: 285-322
33. Kramer MS, Cutler N, Feighner J, et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998; 281: 1640-5
34. Kramer MS, Winokur A, Kelsey J, et al. Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology 2004; 29: 385-92
35. Rupniak NM, Carlson EC, Harrison T, et al. Pharmacological blockade or genetic deletion of substance P (NK1) receptors attenuates neonatal vocalisation in guinea-pigs and mice. Neuropharmacology 2000; 39: 1413-21
36. Rupniak NM, Carlson EJ, Webb JK, et al. Comparison of the phenotype of NK1R-/-mice with pharmacological blockade of the substance P (NK1) receptor in assays for antidepressant and anxiolytic drugs. Behav Pharmacol 2001; 12: 497-508
37. Papp M, Vassout A, Gentsch C. The NK1-receptor antagonist NKP608 has an antidepressant-like effect in the chronic mild stress model of depression in rats. Behav Brain Res 2000; 115: 19-23
38. Froger N, Gardier AM, Moratalla R, et al. 5-hydroxytryptamine (5-HT)1A autoreceptor adaptive changes in substance P (neurokinin 1) receptor knock-out mice mimic antidepressant-induced desensitization. J Neurosci 2001; 21: 8188-97
39. 1A autoreceptor in mice. J Neurochem 2005. In press
40. Froger N, Boni C, Melfort M, et al. Enhanced brain glucocorticoid receptor expression in mice lacking substance P NK1 receptors [abstract 088.8]. FENS Forum 2002; 342
41. Barden N. Regulation of corticosteroid receptor gene expression in depression and antidepressant action. J Psychiatry Neurosci 1999; 24: 25-39
42. Lanfumey L, Mannoury La Cour C, Froger N, et al. 5-HT-HPA interactions in two models of transgenic mice relevant to major depression. Neurochem Res 2000; 25: 1199-206
43. Reul JM, Labeur MS, Grigoriadis DE, et al. Hypothalamic-pituitary- adrenocortical axis changes in the rat after long-term treatment with the reversible monoamine oxidase-A inhibitor moclobemide. Neuroendocrinology 1994; 60: 509-19
44. Seckl JR, Fink G. Antidepressants increase glucocorticoid and mineralocorticoid receptor mRNA expression in rat hippocampus in vivo. Neuroendocrinology 1992; 55: 621-6
45. Przegalinski E, Budziszewska B. The effect of long-term treatment with antidepressant drugs on the hippocampal mineralocorticoid and glucocorticoid receptors in rats. Neurosci Lett 1993; 161: 215-8
46. Calfa G, Kademian S, Ceschin D, et al. Characterization and functional significance of glucocorticoid receptors in patients with major depression: modulation by antidepressant treatment. Psychoneuroendocrinology 2003; 28: 687-701
47. Nickel T, Sonntag A, Schill J, et al. Clinical and neurobiological effects of tianeptine and paroxetine in major depression. J Clin Psychopharmacol 2003; 23: 155-68
48. Griebel G, Simiand J, Steinberg R, et al. 4-(2-chloro-4-methoxy-5- methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl) ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II. Characterization in rodent models of stress-related disorders. J Pharmacol Exp Ther 2002; 301: 333-45
49. Ducottet C, Griebel G, Belzung C. Effects of the selective nonpeptide corticotropin-releasing factor receptor 1 antagonist antalarmin in the chronic mild stress model of depression in mice. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 625-31
50. Alonso R, Griebel G, Pavone G, et al. Blockade of CRF(1) or V(1b) receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression. Mol Psychiatry 2004; 9: 278-86
51. Serradeil-Le Gal C, Wagnon J, Simiand J, et al. Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl) sulfonyl]-3-(2-methoxy-phenyl)-2- oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist. J Pharmacol Exp Ther 2002; 300: 1122-30
52. Griebel G, Simiand J, Serradeil-Le Gal C, et al. Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc Natl Acad Sci U S A 2002; 99: 6370-5
53. Pepin MC, Pothier F, Barden N. Impaired type II glucocorticoid-receptor function in mice bearing antisense RNA transgene. Nature 1992; 355: 725-8
54. Froger N, Palazzo E, Boni C, et al. Neurochemical and behavioral alterations in glucocorticoid receptor-impaired transgenic mice after chronic mild stress. J Neurosci 2004; 24: 2787-96
55. Wolkowitz OM, Reus VI. Treatment of depression with antiglucocorticoid drugs. Psychosom Med 1999; 61: 698-711
56. Belanoff JK, Rothschild AJ, Cassidy F, et al. An open label trial of C-1073 (mifepristone) for psychotic major depression. Biol Psychiatry 2002; 52: 386-92
57. Benca RM, Obermeyer WH, Thisted RA, et al. Sleep and psychiatric disorders: a meta-analysis. Arch Gen Psychiatry 1992; 49: 651-68
58. 1A receptors in the rat brain. Neuropharmacology 2004; 47: 515-26
59. Krauchi K, Cajochen C, Mori D, et al. Early evening melatonin and S-20098 advance circadian phase and nocturnal regulation of core body temperature. Am J Physiol 1997; 272: R1178-88
60. Papp M, Gruca P, Boyer PA, et al. Effect of agomelatine in the chronic mild stress model of depression in the rat. Neuropsychopharmacology 2003; 28: 694-703
61. Bourin M, Mocaer E, Porsolt R. Antidepressant-like activity of S-20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors. J Psychiatry Neurosci 2004; 29: 126-33
62. Loo H, Hale A, D'Haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 2002; 17: 239-47
63. Sheline YI, Wang PW, Gado MH, et al. Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci U S A 1996; 93: 3908-13
64. Sheline YI, Sanghavi M, Mintun MA, et al. Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. J Neurosci 1999; 19: 5034-43
65. Taupin P, Gage FH. Adult neurogenesis and neural stem cells of the central nervous system in mammals. J Neurosci Res 2002; 69: 745-9
66. Weiss S, Reynolds BA, Vescovi AL, et al. Is there a neural stem cell in the mammalian forebrain? Trends Neurosci 1996; 19: 387-93
67. Snyder JS, Kee N, Wojtowicz JM. Effects of adult neurogenesis on synaptic plasticity in the rat dentate gyrus. J Neurophysiol 2001; 85: 2423-31
68. van Praag H, Schinder AF, Christie BR, et al. Functional neurogenesis in the adult hippocampus. Nature 2002; 415: 1030-4
69. Manji HK, Drevets WC, Charney DS. The cellular neurobiology of depression. Nat Med 2001; 7: 541-7
70. McEwen BS, Magarinos AM. Stress and hippocampal plasticity: implications for the pathophysiology of affective disorders. Hum Psychopharmacol 2001; 16: S7-S19
71. Finkbeiner S. CREB couples neurotrophin signals to survival messages. Neuron 2000; 25: 11-4
72. Duman RS, Malberg J, Nakagawa S, et al. Neuronal plasticity and survival in mood disorders. Biol Psychiatry 2000; 48: 732-9
73. Malberg JE, Eisch AJ, Nestler EJ, et al. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 2000; 20: 9104-10
74. Duman RS, Nakagawa S, Malberg J. Regulation of adult neurogenesis by antidepressant treatment. Neuropsychopharmacology 2001; 25: 836-44
75. Santarelli L, Saxe M, Gross C, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003; 301: 805-9
76. Chen G, Rajkowska G, Du F, et al. Enhancement of hippocampal neurogenesis by lithium. J Neurochem 2000; 75: 1729-34
77. Morcuende S, Gadd CA, Peters M, et al. Increased neurogenesis and brain-derived neurotrophic factor in neurokinin-1 receptor gene knockout mice. Eur J Neurosci 2003; 18: 1828-36
78. Rupniak NM. Elucidating the antidepressant actions of substance P (NK1 receptor) antagonists. Curr Opin Investig Drugs 2002; 3: 257-61
79. Morley-Fletcher S, Mairesse J, Mocaer E, et al. Chronic treatment with agomelatine increases hippocampal cell proliferation in prenatally stressed rats. Neurosci Abst 2003; 506.20
80. Daszuta A, Banasr M, Hery M, et al. Agomelatine, a new antidepressant drug, increases cell proliferation in adult hippocampus. Neurosci Abst 2003; 849.3